Serono announced the discontinuation of two phase 3 clinical trial programs; onercept (recombinant tumor necrosis factor binding protein) in moderate-to-severe psoriasis and Canvaxin in Stage IV melanoma, licensed from CancerVax.
ChoicePoint Discontinues Sale of Certain Info Products
ChoicePoint Chairman and CEO Derek V. Smith announced that the company will discontinue the sale of information products that contain sensitive consumer data.